e d i t o r i a l s
T h e ne w e ngl a nd jou r na l o f m e dic i ne Several treatments (e.g., bed rest, bracing, and pain medications) have been designed to foster pain relief and allow for increased activities. Per cutaneous vertebroplasty -the injection of poly methylmethacrylate directly into the vertebral com pression fracture -has emerged as a treat ment option. 4 It is proposed that cement injected directly into the fracture provides immediate sta bility and relief of pain. Despite several studies suggesting a positive treatment effect for verte broplasty, as compared with control treatments, there have been no blinded or placebocontrolled, randomized trials.
During the past 6 years, the number of verte broplasty procedures performed in the United States has doubled, from 4.3 to 8.9 per 1000 per sons, with variation across geographic areas by nearly a factor of 30 (Fig. 1 , and the figure in the Supplementary Appendix, available with the full text of this article at NEJM.org). The first two blinded, randomized, placebocontrolled trials of vertebroplasty are reported in this issue of the Journal, 5, 6 and the results may change vertebro plasty from a procedure that is virtually always considered to be successful to one that is consid ered no better than placebo.
In investigating the treatment of subjective re ports of pain and decreased function, the only way to distinguish the effect of expectations by the patients from the intervention itself is to conceal the treatment from the patients. Two unblinded trials have compared vertebroplasty with medical management: one showed better pain relief with vertebroplasty at 1 day and 2 weeks, 7 and the other showed no significant difference at 3 months. 8 In the Investigational Vertebroplasty Safety and Efficacy Trial (INVEST) (ClinicalTrials.gov num ber, NCT00068822), Kallmes et al. 5 report that pain and disability outcomes at 1 month in a group of patients who underwent vertebroplasty were similar to those in a control group that un derwent a sham procedure, with a trend toward a higher rate of clinically meaningful improve ment in the vertebroplasty group. Both study groups showed improvement within 3 days after the procedure. The cutoff for the primary out come was 1 month, but data were collected for 3 months. Because of crossover to the other group, the intentiontotreat analysis at 3 months prob ably underestimated the true treatment effect, whereas an astreated analysis probably would have overestimated the effect.
Interestingly, patients in the two groups (who were still unaware of which procedure they had received) crossed over to the other group after 1 month. The patients who crossed over had worse outcomes than those who did not request the other intervention. Since more patients than pre dicted were able to guess which treatment they had received, there might have been a benefit in understanding the treatment effect in those who guessed their treatment accurately. Did those who received vertebroplasty and guessed correctly do better or worse than those who did not guess correctly?
T h e ne w e ngl a nd jou r na l o f m e dic i ne
In the other trial, Buchbinder et al. (Australian New Zealand Clinical Trials Registry number, ACTRN012605000079640) 6 measured pain, qual ity of life, and functional status at 1 week and at 1, 3, and 6 months after sham and active verte broplasty and found there were no significant betweengroup differences at any time point. As in INVEST, patients in the two study groups had improvement in pain.
In both trials, the placebo procedure involved the injection of a shortacting analgesic into the bony periosteum containing nociceptive fibers, which make the area very sensitive to manipula tion. Given the limited effect of vertebroplasty and no significant difference between treatments, was the placebo an active treatment?
Compassionate care and tincture of time, in and of themselves, can have an effect. After all, it is natural for fractures to heal. However, there is physical evidence of altered fracture healing in osteoporotic bone, which might have important implications in the treatment of osteoporotic frac tures. 9 During 6 months of followup, Buchbinder et al. reported seven incident fractures. 6 Adverse events were infrequent in these tri als; however, vertebroplasty is not without risks. Reported complications, such as softtissue dam age and nerveroot pain and compression, are re lated specifically to the leakage of bone cement. Rarely reported complications include pulmonary embolism, respiratory and cardiac failure, and death. 10, 11 Given the increasing use, limited benefit, and potential risk, how often should vertebroplasty be performed? When best evidence suggests a toss up between treatment options and no benefit, in formed patient choice is essential. When faced with several choices for which the evidence is less than clear, patients and doctors must thoroughly review the options together. Informed choice helps The map shows ratios of vertebroplasty rates across the country to the national average of 0.73 procedures per 1000 Medicare enrollees. A total of 66 regions had rates that were at least 30% higher than the national average; 105 regions had rates that were more than 25% lower. The three regions with highest rates per 1000 Medicare enrollees were Topeka, Kansas (3.47); Asheville, North Carolina (3.14); and Fort Wayne, Indiana (2.67). The rates were lowest in Newark, New Jersey (0.13); Albany, New York (0.13); and Manhattan, New York (0.12). Data are from the Centers for Medicare and Medicaid Services. to educate patients about treatment options and allows them to recognize that a decision can be based on their values and preferences. 12 This process also applies to cases in which the evidence for various options is available and in which each decision maker might value the riskbenefit profile for each option differently. Physi cians typically underestimate patients' desires for information. 13 Active involvement by patients in their treatment choice leads to decisions that re flect the patients' values, and patients tend to choose the most effective treatment, consistent with the best evidence. Patients who use decision aids are less likely to choose an invasive surgical procedure over a more conservative approach. 14, 15 President Barack Obama has called for more comparativeeffectiveness research as part of the American Recovery and Reinvestment Act. Al though clinical trials are an integral part of such research, from a safety and effectiveness stand point, data from clinical trials combined with those from registries or other large longitudinal databases are necessary to provide the best evi dence. Americans prize advances in technology. However, if in major medical challenges, such as osteoporotic vertebral compression fractures, the alternative is to pay the cost of perpetual uncer tainty, we need to support the research necessary to provide sufficient efficacy and safety informa tion for patients to make a truly informed choice. Although the trials by Kallmes et al. and Buch binder et al. provide the best available scientific evidence for an informed choice, it remains to be seen whether there will be a paradigm shift in the treatment of vertebral compression fractures with vertebroplasty or similar procedures.
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